Inogen, Inc. (INGN) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: 18.01
30Y Low18.0·High61.8
P/FCF
N/A
—
5yr avg: N/A
30Y Low32.3·High61.6
P/B Ratio
↓
0.91
↓-29% vs avg
5yr avg: 1.28
30Y Low0.6·High11.5
ROE
↓
-12.4%
↓+37% vs avg
5yr avg: -19.8%
30Y Low-41%·High60%
Debt/EBITDA
N/A
—
5yr avg: 0.86
30Y Low0.0·High6.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
INGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Inogen, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $174M | $183M | $217M | $127M | $450M | $765M | $982M | $1.5B | $2.8B | $2.6B | $1.4B |
| Enterprise Value | $87M | $96M | $123M | $24M | $287M | $556M | $780M | $1.3B | $2.6B | $2.5B | $1.3B |
| P/E Ratio → | -7.54 | — | — | — | — | — | — | 72.69 | 53.99 | 124.04 | 69.25 |
| P/S Ratio | 0.50 | 0.52 | 0.65 | 0.40 | 1.19 | 2.14 | 3.18 | 4.20 | 7.81 | 10.45 | 6.99 |
| P/B Ratio | 0.91 | 0.95 | 1.25 | 0.62 | 1.51 | 2.07 | 2.81 | 4.41 | 9.01 | 11.49 | 7.78 |
| P/FCF | — | — | — | — | — | — | 49.93 | 44.59 | 59.48 | 51.88 | 61.56 |
| P/OCF | — | — | 36.68 | — | — | 32.36 | 26.53 | 37.44 | 46.61 | 43.11 | 45.66 |
P/E links to full P/E history page with 30-year chart
INGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.28 | 0.36 | 0.07 | 0.76 | 1.55 | 2.53 | 3.67 | 7.26 | 9.88 | 6.53 |
| EV / EBITDA | — | — | — | — | — | 18.01 | 118.99 | 39.51 | 52.84 | 61.78 | 36.36 |
| EV / EBIT | — | — | — | — | — | 60.15 | — | 67.13 | 68.59 | 89.33 | 57.91 |
| EV / FCF | — | — | — | — | — | — | 39.66 | 38.98 | 55.29 | 49.03 | 57.53 |
INGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Inogen, Inc. earns an operating margin of -8.7%. Operating margins have expanded from -34.7% to -8.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -12.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.6% | 47.6% | 46.1% | 40.1% | 40.7% | 49.3% | 44.8% | 47.5% | 49.9% | 48.6% | 48.0% |
| Operating Margin | -8.7% | -8.7% | -12.7% | -34.7% | -22.6% | 2.6% | -3.9% | 5.5% | 10.6% | 11.1% | 11.3% |
| Net Profit Margin | -6.5% | -6.5% | -10.7% | -32.5% | -22.2% | -1.8% | -1.9% | 5.8% | 14.5% | 8.4% | 10.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -12.4% | -12.4% | -19.0% | -40.8% | -25.1% | -1.8% | -1.7% | 6.4% | 19.3% | 10.3% | 13.0% |
| ROA | -7.6% | -7.6% | -11.5% | -28.0% | -18.7% | -1.3% | -1.3% | 5.1% | 15.9% | 8.6% | 10.9% |
| ROIC | -24.4% | -24.4% | -35.3% | -69.8% | -43.3% | 4.5% | -6.0% | 11.1% | 28.7% | 23.9% | 21.8% |
| ROCE | -13.3% | -13.3% | -18.0% | -36.9% | -22.2% | 2.2% | -3.0% | 5.4% | 13.3% | 12.8% | 13.8% |
INGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $104M exceeds total debt of $17M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.11 | 0.11 | 0.08 | 0.07 | 0.03 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.86 | 1.53 | 0.20 | — | — | — |
| Net Debt / Equity | — | -0.45 | -0.54 | -0.51 | -0.55 | -0.56 | -0.58 | -0.56 | -0.63 | -0.63 | -0.51 |
| Net Debt / EBITDA | — | — | — | — | — | -6.77 | -30.80 | -5.69 | -4.00 | -3.58 | -2.55 |
| Debt / FCF | — | — | — | — | — | — | -10.27 | -5.61 | -4.18 | -2.84 | -4.03 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | 3810.67 |
Net cash position: cash ($104M) exceeds total debt ($17M)
INGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Inogen, Inc.'s current ratio of 3.12x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.71x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.86x to 3.12x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.12 | 3.12 | 2.42 | 2.86 | 4.66 | 5.35 | 5.39 | 5.82 | 6.75 | 6.74 | 7.07 |
| Quick Ratio | 2.71 | 2.71 | 2.09 | 2.55 | 4.14 | 4.83 | 4.95 | 5.11 | 6.17 | 6.19 | 6.44 |
| Cash Ratio | 1.88 | 1.88 | 1.48 | 1.77 | 2.86 | 3.99 | 4.08 | 4.17 | 5.16 | 5.13 | 4.99 |
| Asset Turnover | — | 1.17 | 1.13 | 0.97 | 0.93 | 0.73 | 0.67 | 0.81 | 0.95 | 0.91 | 0.95 |
| Inventory Turnover | 7.04 | 7.04 | 7.29 | 8.65 | 6.56 | 5.70 | 6.86 | 5.33 | 6.63 | 6.80 | 7.36 |
| Days Sales Outstanding | — | 40.68 | 32.73 | 49.62 | 62.26 | 26.30 | 37.58 | 37.62 | 40.46 | 47.93 | 55.48 |
INGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Inogen, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 1.4% | 1.9% | 0.8% | 1.4% |
| FCF Yield | — | — | — | — | — | — | 2.0% | 2.2% | 1.7% | 1.9% | 1.6% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $27M | $24M | $23M | $23M | $22M | $22M | $22M | $23M | $22M | $21M |
Peer Comparison
Compare INGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 INGNYou | $174M | -7.5 | — | — | 47.6% | -8.7% | -12.4% | -24.4% | — |
 LNTH | $7B | 30.5 | 16.8 | 19.1 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 CRVL | $3B | 27.3 | 19.2 | 0.0 | 24.3% | 14.9% | 30.8% | 59.4% | 0.1 |
 APOG | $888M | 16.4 | 24.1 | 9.3 | 22.7% | 6.0% | 10.8% | 8.1% | 6.1 |
 PHM | $24B | 11.4 | 8.0 | 14.0 | 26.4% | 17.3% | 17.7% | 17.2% | 0.8 |
 LUNG | $54M | -1.0 | — | — | 74.2% | -59.3% | -77.2% | -72.0% | — |
 SPXC | $12B | 48.0 | 24.5 | 50.5 | 36.7% | 16.8% | 13.6% | 13.4% | 1.0 |
 LINC | $2B | 74.5 | 33.7 | — | 60.4% | 5.8% | 10.6% | 6.7% | 4.0 |
 LIN | $237B | 35.1 | 20.4 | 46.6 | 43.3% | 26.3% | 17.4% | 11.3% | 2.1 |
 APD | $62B | -158.3 | 114.9 | — | 31.4% | -7.3% | -2.2% | -2.0% | 26.8 |
 OXLC | $812M | -1.4 | — | 1.2 | 68.2% | -135.4% | -39.2% | -18.7% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
INGN — Frequently Asked Questions
Quick answers to the most common questions about buying INGN stock.
What is Inogen, Inc.'s P/E ratio?
Inogen, Inc.'s current P/E ratio is -7.5x. The historical average is 82.7x.
What is Inogen, Inc.'s ROE?
Inogen, Inc.'s return on equity (ROE) is -12.4%. The historical average is 0.1%.
Is INGN stock overvalued?
Based on historical data, Inogen, Inc. is trading at a P/E of -7.5x. Compare with industry peers and growth rates for a complete picture.
What are Inogen, Inc.'s profit margins?
Inogen, Inc. has 47.6% gross margin and -8.7% operating margin.